SCHEMBL26742261

SCHEMBL26742261

CCOC(=O)c1cccnc1Nc1cccc(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.56
MAPT P10636 7/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPK1 P28482 3/20 0.53
PKM P14618 1/20 0.53
TP53 P04637 1/20 0.53
HPGD P15428 2/20 0.51
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
LMNA P02545 2/20 0.50
SYK P43405 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
AHR P35869 1/20 0.49
SIRT5 Q9NXA8 1/20 0.48
ELANE P08246 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7272758 0.88 KMT2A (0.60) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL11833609 0.87 HTT (0.68) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL8689929 0.85 LMNA (0.69) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL8693048 0.85 ELANE (0.52) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL11790155 0.84 KMT2A (0.69) HTTMAPTL3MBTL1MEN1KMT2A
SCHEMBL7446183 0.83 HTT (0.55) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL10378109 0.83 HTT (0.54) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL10144303 0.83 MEN1 (0.71) HTTMAPTL3MBTL1MEN1KMT2A
SCHEMBL11830768 0.82 DHODH (0.56) HTTMAPTMEN1KMT2AMAPK1
SCHEMBL5083062 0.82 RAB9A (0.72) HTTMAPTMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346765-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346765-A1 METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF XDH, PNPO, PNP HTT 1767/4885MAPT 2521/4885L3MBTL1 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.